Novel multitargeted anticancer oral therapies: Sunitinib and sorafenib as paradigm

Israel Medical Association Journal

Volumn 12, Issue 10, 2010, Pages 628-632

  Sulkes, Aaron ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Gastrointestinal stromal tumors; Hepatocellular carcinoma; Multitargeted anticancer oral therapies; Renal cell carcinoma; Sorafenib; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; IMATINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPIGMENTATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LABORATORY TEST; LIVER CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHRECTOMY; PATIENT MONITORING; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; STOMATITIS; THYROID DISEASE; THYROID FUNCTION TEST; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES;

EID: 78449253608     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Mendel DB, Laird AD, Sin X, et al. In vivo antitumor activity 1. of SU-11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokineticpharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
2. Lacy CF, Armstrong LL, Goldman MP. Cytochrome P-450 enzymes and drug metabolism In: Lacy DV, Armstrong LL, Goldman MP, eds. Drug Information Handbook. 12th edn. Hudson, OH, 2004: 1619-31.
3. Sico DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24: 1329-1331.
4. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007; 18: 1117.
5. Chu TF, Repnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor Sunitinib. Lancet 2007; 370: 2001-2019.
6. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-83.
7. Moss KG, Toner GC, Cherrington JM, et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003; 307: 476-480.
8. Robert C, Soria JC, Spatz A, et al. Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
9. Motzer RJ, Rini BI, Bukowski RM. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
10. Kollmannsberger C, Soulieres D, Wong R, et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1: S41-54.
11. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
12. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
13. Sternberg CN. Expanding the boundaries of clinical practice: building on experience with targeted therapies. Ann Oncol 2009; 20(Suppl 1): il-6.
14. Houk B, Bello LL, Michaelson MD, et al. A population/pharmacodynamic analysis of exposure-response for sunitinib in metastatic renal cell carcinoma. Eur J Cancer 2007; 5(Suppl): 299.
15. Zimmerman K, Schmittel A, Steiner U, et al. sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76: 350-354.
16. Bellmunt J. Future developments in renal cell carcinoma. Ann Oncol 2009; 20(Suppl 1): i13-17.
17. Demetri GD, Van Oosterom AT, Garrett R, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumors after failure of imatinib: a randomized controlled trial. Lancet 2006; 368: 1329-1338.
18. Reichardt P, Kang Y, Ruka W, et al. Detailed analysis of survival and safety with sunitinib in a worldwide treatment-use trial in patients with advanced GIST. J Clin Oncol 2008; 26 (May 20 suppl): Abstr 10548.
19. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib maleate in imatinib-resistant gastrointestinal stromal tumors. J Clin Oncol 2008; 26: 5352-5359.
20. Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-1096.
21. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008; 19: 265-268.
22. Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007; 356: 125-134.
23. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007; 25(June 20 suppl): Abstr 5023.
24. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first line treatment with sorafenib versus Interferon in patients with advanced renal cell carcinoma. Final results. J Clin Oncol 2007; 25: 5025-5050.
25. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714.
26. Ansari J, Fatima A, Chaudhri S, et al. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 2009; 32: 44-46.
27. Chouriri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.
28. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
29. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.
30. Nimeiri HS, Maki RG, Kasaza K, et al. Activity of sorafenib in patients with Imatinib and sunitinib-resistant gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago phase II Consortium. Soc Clin Oncol GI Cancers Symposium, 2008: Abstr 7m